Home LiteratureArticle Details
PMID: 17435285 Published · ppublish English Comparative Study Journal Article Review

Methods and goals for the use of in vitro and in vivo chemosensitivity testing.

Molecular biotechnology ·Vol. 35 ·No. 2 ·2007-02-00 ·Pages 185-97

Blumenthal RD, Goldenberg DM

Abstract

Sensitive, specific, and accurate methods to assay chemosensitivity are needed to (1) screen new therapeutic agents, (2) identify patterns of chemosensitivity for different tumor types, (3) establish patterns of cross-resistance and sensitivity in treatment of naïve and relapsing tumors, (4) identify genomic and proteomic profiles associated with sensitivity, (5) correlate in vitro response with preclinical in vivo effects and clinical outcomes for a particular therapeutic agent, and (6) tailor chemotherapy regimens to individual patients. Various methods are available to achieve these end points, including several in vitro clonogenic and proliferation assays, cell metabolic activity assays, molecular assays to monitor expression of markers for responsiveness, drug resistance, and for induction of apoptosis, in vivo tumor growth and survival assays in metastatic and orthotopic models, and in vivo imaging assays. The advantages and disadvantages of the specific assays are discussed. A summary of research questions related to chemosensitivity testing is also included.

MeSH Terms
Animals Antineoplastic Agents/pharmacology Biotechnology Cell Proliferation/drug effects Cell Survival/drug effects Drug Resistance, Neoplasm/genetics Drug Screening Assays, Antitumor/methods,statistics & numerical data Genomics Humans In Vitro Techniques Neoplasms/drug therapy,genetics,metabolism,pathology Neoplasms, Experimental/drug therapy,genetics,metabolism,pathology Proteomics Sensitivity and Specificity Tumor Stem Cell Assay
Chemicals
Antineoplastic Agents
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Blumenthal Rosalyn D
Garden State Cancer Center, Belleville, NJ 07109, USA. rblumenthal@gscancer.org
Goldenberg David M
References (94)
94 references, click to expand
  1. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.
    Med Biol. 1984;62(6):338-43 PMID: 6543460
  2. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
    Adv Exp Med Biol. 1999;457:77-88 PMID: 10500783
  3. The fluorescent cytoprint assay: a new approach to in vitro chemosensitivity testing.
    Oncology (Williston Park). 1991 Sep;5(9):75-81; discussion 81-2, 85, 88 PMID: 1835881
  4. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production.
    Cancer Res. 1991 May 15;51(10 ):2515-20 PMID: 2021931
  5. Individualized cancer therapy: molecular approaches to the prediction of tumor response.
    Expert Rev Anticancer Ther. 2002 Feb;2(1):113-9 PMID: 12113060
  6. Study of therapy resistance in cancer cells with functional proteome analysis.
    Clin Chem Lab Med. 2002 Mar;40(3):221-34 PMID: 12005211
  7. Three-dimensional histoculture: origins and applications in cancer research.
    Cancer Cells. 1991 Mar;3(3):86-92 PMID: 2054260
  8. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
    Proteomics. 2002 Jan;2(1):76-84 PMID: 11788994
  9. Prediction of response to drug therapy of cancer. A review of in vitro assays.
    Drugs. 1992 Nov;44(5):690-708 PMID: 1280562
  10. Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification.
    Jpn J Cancer Res. 2001 Feb;92(2):203-10 PMID: 11223550
  11. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.
    J Natl Cancer Inst. 1990 Apr 4;82(7):582-8 PMID: 2313735
  12. In vitro chemosensitivity testing and mechanisms of drug resistance.
    Curr Oncol Rep. 1999 Sep;1(1):77-84 PMID: 11122802
  13. Estimation of cell survival by flow cytometric quantification of fluorescein diacetate/propidium iodide viable cell number.
    Cancer Res. 1989 Jul 15;49(14 ):3776-82 PMID: 2736519
  14. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors.
    Cancer Res. 1985 Nov;45(11 Pt 1):5436-41 PMID: 4053017
  15. A simple method for accurate estimation of apoptotic cells.
    Exp Cell Res. 2000 Apr 10;256(1):328-37 PMID: 10739681
  16. Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer.
    Clin Cancer Res. 1997 Sep;3(9):1635-41 PMID: 9815854
  17. Evaluation of cell proliferation and cell death based assays in chemosensitivity testing.
    Anticancer Res. 2001 Jul-Aug;21(4A):2761-8 PMID: 11724352
  18. Chemosensitivity prediction by transcriptional profiling.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10787-92 PMID: 11553813
  19. HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
    Breast Cancer Res Treat. 2001 Sep;69(1):53-63 PMID: 11759828
  20. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling.
    Pharmacol Res. 2006 Jan;53(1):49-61 PMID: 16213748
  21. Metastasis from human breast cancer cell lines.
    Breast Cancer Res Treat. 1996;39(1):93-102 PMID: 8738609
  22. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Cancer Res. 1995 Nov 15;55(22):5276-82 PMID: 7585588
  23. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
    Anticancer Res. 2006 Mar-Apr;26(2B):1651-5 PMID: 16619587
  24. Clonal heterogeneity of p53 mutations in ovarian cancer.
    Int J Oncol. 2001 Aug;19(2):387-94 PMID: 11445857
  25. Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.
    J Neurooncol. 2002 Jun;58(2):115-23 PMID: 12164682
  26. Image analysis for quantitation of solid tumor drug sensitivity.
    Int J Surg Investig. 1999;1(2):133-8 PMID: 11341633
  27. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma.
    Breast Cancer Res Treat. 2000 Jun;61(3):211-6 PMID: 10965997
  28. Ex vivo programmed cell death and the prediction of response to chemotherapy.
    Curr Treat Options Oncol. 2006 Mar;7(2):103-10 PMID: 16455021
  29. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology.
    Ann Nucl Med. 2001 Dec;15(6):471-86 PMID: 11831394
  30. Evaluation of chemosensitivity testing with highly purified tumor cells in 435 patients with gastric carcinoma using an MTT assay.
    Anticancer Res. 2005 Mar-Apr;25(2A):931-7 PMID: 15868930
  31. Evaluating response to antineoplastic drug combinations in tissue culture models.
    Methods Mol Med. 2005;110:173-83 PMID: 15901935
  32. Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines.
    J Cancer Res Clin Oncol. 2000 Apr;126(4):198-204 PMID: 10782892
  33. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers.
    Am J Pathol. 2002 Oct;161(4):1223-33 PMID: 12368196
  34. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.
    Cancer Res. 1983 Feb;43(2):749-57 PMID: 6184155
  35. Microphysiological testing for chemosensitivity of living tumor cells with multiparametric microsensor chips.
    Cancer Detect Prev. 2003;27(4):291-6 PMID: 12893077
  36. Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation.
    Int J Oncol. 1998 Sep;13(3):489-95 PMID: 9683783
  37. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
    J Clin Oncol. 1999 Jun;17(6):1760-70 PMID: 10561213
  38. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer.
    Semin Radiat Oncol. 2002 Oct;12(4):296-304 PMID: 12382188
  39. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay.
    Head Neck. 2002 May;24(5):437-42 PMID: 12001073
  40. Prospective clinical trial of a human tumor cloning system.
    Cancer Res. 1983 Apr;43(4):1926-31 PMID: 6339044
  41. Regulation of tumor cell apoptotic sensitivity during the cell cycle (Review).
    Int J Mol Med. 2000 Nov;6(5):503-7 PMID: 11029514
  42. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays.
    J Clin Oncol. 2004 Sep 1;22(17):3631-8 PMID: 15289488
  43. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
    Breast Cancer Res Treat. 2001 Jun;67(3):223-33 PMID: 11561768
  44. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.
    J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8 PMID: 2359137
  45. Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
    Gynecol Oncol. 1994 Aug;54(2):163-70 PMID: 7520407
  46. Detection of a decrease in green fluorescent protein fluorescence for the monitoring of cell death: an assay amenable to high-throughput screening technologies.
    Cytometry. 2001 Dec 1;45(4):237-43 PMID: 11746092
  47. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein.
    Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):14078-83 PMID: 11707575
  48. Assessment of in vitro drug resistance of human breast cancer cells subcultured from biopsy specimens.
    Anticancer Res. 2003 May-Jun;23 (3B):2593-9 PMID: 12894546
  49. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.
    Cancer Res. 1984 Apr;44(4):1725-8 PMID: 6704978
  50. Cellular drug resistance in childhood acute myeloid leukemia. A mini-review with emphasis on cell culture assays.
    Adv Exp Med Biol. 1999;457:415-21 PMID: 10500817
  51. Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line.
    Cancer Sci. 2003 Jan;94(1):112-8 PMID: 12708484
  52. A fluorescence digital image microscopy system for quantifying relative cell numbers in tissue culture plates.
    Cytometry. 1996 Jul 1;24(3):204-13 PMID: 8800553
  53. Multidrug resistance in haematological malignancies.
    J Intern Med. 2000 May;247(5):521-34 PMID: 10809991
  54. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.
    Gynecol Oncol. 1988 Sep;31(1):191-204 PMID: 3410347
  55. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Cancer Chemother Pharmacol. 2002 Jul;50(1):46-52 PMID: 12111111
  56. A model-based approach for assessing in vivo combination therapy interactions.
    Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13023-8 PMID: 10557266
  57. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer.
    J Natl Cancer Inst. 2002 Jul 17;94(14):1091-9 PMID: 12122100
  58. An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
    Cancer Res. 2000 Nov 1;60(21):6101-10 PMID: 11085534
  59. A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins.
    Cancer Res. 2004 Apr 15;64(8):2805-16 PMID: 15087397
  60. In vitro chemosensitivity testing of hematological cancer patients: detection of ornithine decarboxylase.
    Recent Results Cancer Res. 2003;161:62-70 PMID: 12528799
  61. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
    Clin Cancer Res. 2004 Oct 15;10(20):6897-904 PMID: 15501967
  62. Chronotherapy of colorectal cancer metastases.
    Hepatogastroenterology. 2001 Mar-Apr;48(38):320-2 PMID: 11379299
  63. Role of oncogenes in resistance and killing by cancer therapeutic agents.
    Curr Opin Oncol. 1997 Jan;9(1):79-87 PMID: 9090498
  64. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
    Nature. 2000 Feb 3;403(6769):503-11 PMID: 10676951
  65. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.
    Invest New Drugs. 1999;17(4):343-59 PMID: 10759402
  66. Overexpression of p27 protein in human breast cancer correlates with in vitro resistance to doxorubicin and mitomycin C.
    Anticancer Res. 2000 Nov-Dec;20(6B):4319-22 PMID: 11205265
  67. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins.
    Br J Cancer. 1998 Oct;78(8):986-92 PMID: 9792140
  68. Circulating tumour cells in breast cancer.
    Lancet Oncol. 2004 Feb;5(2):79-88 PMID: 14761811
  69. Statistical analysis of in vivo tumor growth experiments.
    Cancer Res. 1993 Dec 15;53(24):6042-50 PMID: 8261420
  70. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles.
    Cancer Res. 2001 Sep 1;61(17):6474-9 PMID: 11522643
  71. Rapid in vitro chemosensitivity analysis of human colon tumor cell lines.
    Toxicol Appl Pharmacol. 2003 Nov 1;192(3):237-45 PMID: 14575641
  72. Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines.
    Anticancer Drugs. 2001 Mar;12(3):247-58 PMID: 11290872
  73. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
    Br J Haematol. 2000 Mar;108(4):703-9 PMID: 10792272
  74. Role of apoptotic response in cellular resistance to cytotoxic agents.
    Pharmacol Ther. 1997 Oct-Dec;76(1-3):177-85 PMID: 9535179
  75. Comparative image and flow cytometric TUNEL analysis of fine needle samples of breast carcinoma.
    Cytometry. 2001 Jun 15;46(3):150-6 PMID: 11449405
  76. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia.
    Br J Cancer. 1989 Aug;60(2):206-10 PMID: 2765367
  77. Drug-induced DNA damage and tumor chemosensitivity.
    J Clin Oncol. 1990 Dec;8(12):2062-84 PMID: 2230898
  78. In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
    Anticancer Drugs. 2005 Jan;16(1):87-91 PMID: 15613910
  79. In vitro chemosensitivity testing of hematological cancers: immunohistochemical detection of ornithine decarboxylase.
    Anticancer Drugs. 1999 Oct;10(9):797-805 PMID: 10587289
  80. Determination of subcutaneous tumor size in athymic (nude) mice.
    Cancer Chemother Pharmacol. 1989;24(3):148-54 PMID: 2544306
  81. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.
    Int J Cancer. 1998 Feb 20;79(1):27-33 PMID: 9495354
  82. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.
    Eur J Cancer. 2004 Apr;40(6):802-20 PMID: 15120036
  83. Paclitaxel and cisplatin sensitivity of ovarian carcinoma cell lines tested with the 96-well plate clonogenic assay.
    Anticancer Res. 1996 Jul-Aug;16(4A):1743-7 PMID: 8712694
  84. MDR1 reversal: criteria for clinical trials designed to overcome the multidrug resistance phenotype.
    Leukemia. 1996 Jul;10 Suppl 3:S32-S38 PMID: 8656698
  85. Subrenal capsule assay of human tumor chemosensitivity.
    Neoplasma. 1991;38(3):275-84 PMID: 1857448
  86. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
    Breast Cancer Res. 2002;4(3):R3 PMID: 12052255
  87. The in vitro micronucleus technique.
    Mutat Res. 2000 Nov 20;455(1-2):81-95 PMID: 11113469
  88. Identifying genes related to drug anticancer mechanisms using support vector machine.
    FEBS Lett. 2002 Jun 19;521(1-3):109-14 PMID: 12067737
  89. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.
    Clin Cancer Res. 2002 Sep;8(9):2766-74 PMID: 12231515
  90. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts.
    Int J Oncol. 2002 Feb;20(2):379-84 PMID: 11788905
  91. Multidrug resistance in acute leukemia: a comparison of different diagnostic methods.
    Leukemia. 1997 Jul;11(7):1067-72 PMID: 9204993
  92. Human breast cancer cell line xenografts as models of breast cancer. The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines.
    Breast Cancer Res Treat. 1996;39(1):69-86 PMID: 8738607
  93. A simple and rapid method for the detection of poly(ADP-ribose) by flow cytometry.
    Biosci Biotechnol Biochem. 2000 Mar;64(3):510-5 PMID: 10803947
  94. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents.
    Cancer Res. 1994 Nov 15;54(22):5824-30 PMID: 7954409
Article Info
Journal
Molecular biotechnology
Abbr.
Mol Biotechnol
ISSN
1073-6085
DOI
10.1007/BF02686104
Email
rblumenthal@gscancer.org
Published
2007-02-00
Pages
185-97
Language
English
Region
United States
NLM ID
9423533
Subset
IM
External Links
PubMed source DOI: 10.1007/BF02686104 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2